Akebia continues to publish important, clinically relevant data to further physicians’ understanding of Vafseo® ...

Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the and ...

New findings from the CONFIDENCE trial show that combination therapy with finerenone and empagliflozin leads to significantly ...

Heart in Diabetes meeting brings together leaders from the fields of cardiology, endocrinology, nephrology and more to ...

There is a nationwide shortage of pediatric specialists, delaying care for many patients. In some cases, children wait weeks ...

Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating Aspaveli® (pegcetacoplan) for C3 glomerulopathy (C3G ...

Rory Teeters, 7, has cystic fibrosis but with ongoing care in Rapid City from pediatric pulmonologist Dr. James Wallace, she's living her best life.

An analysis of pooled data from two large finerenone trials identified key risk factors for hyperkalemia in patients with CKD ...

In the VALIANT study, EMPAVELI demonstrated a statistically significant 68% proteinuria reduction versus placebo at Week 26, which was sustained at one year. Additionally, patients treated with ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.